{
    "clinical_study": {
        "@rank": "151306", 
        "arm_group": {
            "arm_group_label": "ESS", 
            "arm_group_type": "Experimental", 
            "description": "Prescription medical food erythropoietin stimulating system"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to measure the change in blood values after the\n      administration of an amino acid based erythropoietin stimulating system."
        }, 
        "brief_title": "An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Anemia of Chronic Disease", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Chronic Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. M/F patients 18 years old and over, non-pregnant/lactating\n\n          2. Hemoglobin < 10 female,<11 male\n\n          3. Ferritin > upper limit of normal for lab indicative of chronic anemia\n\n          4. Anemia of chronic disease\n\n          5. Crt. < 3.0\n\n        Exclusion Criteria:\n\n          1. Currently taking other amino acid formulations.\n\n          2. Pregnant or unwilling to use adequate birth control for the duration of the study.\n\n          3. Excessive alcohol or illicit drug use.\n\n          4. Unwilling or unable to sign informed consent.\n\n          5. Myocardial infarction within the last 6 months.\n\n          6. Patients ever having taken or currently taking an erythropoietin medication.\n\n          7. Iron deficiency (add criteria).\n\n          8. On dialysis.\n\n          9. Malignancy other than non-melanoma skin cancer within the last 5 years. If has such\n             malignancy, must have documentation of no recurrence for at least 5 years.\n\n         10. Liver cirrhosis (add criteria)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01846689", 
            "org_study_id": "E130426"
        }, 
        "intervention": {
            "arm_group_label": "ESS", 
            "description": "Prescription medical food erythropoietin stimulating system", 
            "intervention_name": "ESS (medical food/drug)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Epoetin Alfa"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 30, 2013", 
        "location": {
            "contact": {
                "email": "spavlik@ptlcentral.com", 
                "last_name": "Stephanie Pavlik, CRA", 
                "phone": "310-474-9809"
            }, 
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90077"
                }, 
                "name": "Targeted Medical Pharma"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Trial of an Erythropoietin Stimulating System to Determine Increased Red Blood Cell Production in Subjects Diagnosed With Anemia of Chronic Disease", 
        "overall_contact": {
            "email": "spavlik@ptlcentral.com", 
            "last_name": "Stephanie Pavlik, CRA", 
            "phone": "310-474-9809"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Hemoglogin/Hematocrit", 
            "safety_issue": "No", 
            "time_frame": "28 Days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01846689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Red blood cell count", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "measure": "Reticulocyte count", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "IGF-1", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Targeted Medical Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Targeted Medical Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}